Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020-Reference-Cited by-同舟云学术

Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020

Published:2020-07-16 Issue:28 Volume:25 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Harvala Heli¹,Mehew Jennifer²,Robb Matthew L²,Ijaz Samreen³,Dicks Steven¹³,Patel Monika⁴,Watkins Nicholas⁵,Simmonds Peter⁶,Brooks Tim⁷,Johnson Rachel²,Gopal Robin⁴,Roberts David J⁸⁹,Zambon Maria³,

Affiliation:

1. Microbiology Services, NHS Blood and Transplant, London, United Kingdom

2. Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom

3. Virology Reference Department, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom

4. High Containment Microbiology, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom

5. NHS Blood and Transplant, Cambridge, United Kingdom

6. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

7. Rare & Imported Pathogens Laboratory, Public Health England, Porton Down, United Kingdom

8. Radcliffe Department of Medicine and BRC Haematology Theme, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

9. NHS Blood and Transplant, Oxford, John Radcliffe Hospital, Oxford, United Kingdom

Abstract

Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference20 articles.

1. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.;Nat Microbiol,2020

2. Effectiveness of convalescent plasma therapy in severe COVID-19 patients.;Duan;Proc Natl Acad Sci USA,2020

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Convalescent plasma from Norwegian blood donors to treat COVID-19;Tidsskrift for Den norske legeforening;2023-07-26

2. Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection;Frontiers in Immunology;2023-02-17

3. Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization;Transfusion;2022-06-02

4. Rapid Detection of Anti-SARS-CoV-2 Antibodies with a Screen-Printed Electrode Modified with a Spike Glycoprotein Epitope;Biosensors;2022-04-26

5. Convalescent plasma for COVID ‐19: Donor demographic factors associated high neutralising antibody titres;Transfusion Medicine;2022-04-17